Gavin P. Dunn

Immunology and Microbiology · Life Sciences

56h-index30.0kcitations1.1kworks0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(642), Cancer Research and Treatments(395), vaccines and immunoinformatics approaches(371), RNA Interference and Gene Delivery(320), Cancer Immunotherapy and Biomarkers(165)

Publications1.1k total

Supplementary Figure S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Figure S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S3 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Figure S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S10 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S4 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S6 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Figure S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S2 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S1 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
Supplementary Table S5 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
2026Open Access
A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment
The Lancet Oncology·2025· 1 cited
A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making
The Lancet Oncology·2025· 1 cited
Targeting myeloid cell polarization to prevent GBM recurrence
Molecular Therapy·2025Open Access
Immunotherapy and targeted therapy for high grade gliomas: current and future directions
Journal of Neuro-Oncology·2025
ImmunoNX: a robust bioinformatics workflow to support personalized neoantigen vaccine trials.
PubMed·2025
Supplementary Data from The Conventional Dendritic Cell 1 Subset Primes CD8<sup>+</sup> T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain
2025Open Access
page 1 of 54Next →

Frequent Co-authors

Robert D. Schreiber(12), Tanner M. Johanns(8), Ravindra Uppaluri(8), Eric C. Leuthardt(7), Elaine R. Mardis(6), Albert H. Kim(6), Michael R. Chicoine(6), Peter E. Fecci(5), Malachi Griffith(5), Obi L. Griffith(5), Douglas R. Adkins(5), Christopher A. Miller(5), Allen T. Bruce(4), Lloyd J. Old(4), Mark S. Diamond(4), J. Michael White(4), Kathleen C. F. Sheehan(4), Katie M. Campbell(4), Zachary L. Skidmore(4), Dorina Kallogjeri(4)